

Baxter

Prismaflex

Trusted. Versatile. Reliable.




prismaflex

Making Possible Personal.

No two patients are the same

Every patient that comes into the ICU is different, which means therapies need to be individualised to meet complex, specialised and varied patient needs.

Meeting the need for individualised therapies can put pressure on ICU resources



Prismaflex is a single device that provides individualised and effective therapies for patients, which could help simplify the complexities faced by the ICU and ease the burden on ICU resources.

How can the Prismaflex system simplify individualised CRRT prescriptions?

- Intuitive step-by-step instructions
- All CRRT modalities can be performed using a single set that automatically loads and primes
- Compatible with a wide range of membranes for individual patient needs, including low body weight patients
- Able to deliver regional citrate anticoagulation in all CRRT modes
- Baxter's CRRT fluid offering includes a range of products to suit each patient's specific needs

Prismaflex is an easy-to-learn system offering confidence in prescribing and initiating therapy suited to your patients' needs.

What benefits can the Prismaflex system offer your ICU team?

Smart alarm system can analyse and self-correct problems, optimising treatment while reducing the number of manual interventions required



Pre-connected sets to avoid contamination



Colour-coded lines and barcode reader* give confidence and reassurance in accurate therapy delivery, which may reduce the risk of human error



Fluid detection system to alert to leakage



Automated pressure monitoring and calibration with real-time tracking



Accurate fluid management through a scale-based system and intelligent algorithms



Automatic adjustment of flow rates in case of fluid disbalance



Automatic adjustment of flow rates to ensure the delivery of the prescribed anticoagulation dose (in RCA)



History screen that provides comprehensive overview of key treatment parameters and helps to monitor the prescription



Patented air removal chamber to eliminate the need for manual air removal



Battery back-up to ensure treatment continuity



The Prismaflex system has unique, integrated safety features designed for improved therapy accuracy and reduction of risk.

*The set will be automatically loaded, primed and recognised by the machine through the barcode reader.
RCA, regional citrate anticoagulation.

How can the Prismaflex system ease the delivery of multi-organ support?

Prismaflex is a versatile, user-friendly system that delivers single or combined intensive care therapies without the need for any additional equipment, offering operational and training efficiencies.

OXIRIS BLOOD PURIFICATION

The First Set for 3-in-1 CRRT-Sepsis Management

Blood purification beyond CRRT by targeting cytokines and endotoxin removal with the **oXiris** set.

oXiris is a single-use set comprised of a hollow fiber membrane and tubing lines.¹

The **oXiris** set is indicated for use with the Prismaflex control unit. It is intended for patients in need of blood purification, including continuous renal replacement therapy, and in conditions where excessive endotoxin and inflammatory mediators levels exist.¹

The **oXiris** set combines 3 functionalities in a single device, with multiple potential benefits for critically ill patients in need of blood purification.¹⁻⁸

1. The **oXiris** membrane has capacity to adsorb endotoxin
2. The **oXiris** membrane has capacity to adsorb cytokines & other components involved in the inflammatory response to sepsis
3. With diffusive, convective and adsorptive properties, the **oXiris** membrane provides

removal of toxins and excess fluid via a choice of CRRT modalities to support renal function and fluid management in critically ill patients with AKI.

To support therapy efficiency, the **oXiris** set includes a heparin-grafted membrane designed to reduce membrane thrombogenicity



CRRT FLUIDS

CRRT solutions with physiologically balanced profiles available in convenient, ready-to-use bags with multiple formulations to meet individual patient needs, including:


- Bicarbonate-buffered solutions with various potassium and glucose levels to respond to each patient's specific condition
- Low-concentrated citrate replacement fluid registered as a drug for regional anticoagulation of the extracorporeal circuit*
- Innovative phosphate-containing solutions for haemodialysis and haemofiltration that may prevent electrolyte imbalances during prolonged CRRT^{9,10}, including one low-bicarbonate, calcium-free formula designed for CRRT using regional citrate anticoagulation



THERAPEUTIC PLASMA EXCHANGE AND HAEMOPERFUSION

Simple and safe blood purification treatment:

- TPE sets for plasma protein removal in both adults and children (≥ 9 kg)
- Pre-connected lines facilitate platform installation for ease of use
- Two sizes of HP kits for chemical or drug intoxication; include activated charcoal column and associated bloodlines
- The **Prismaflex** system simplifies the implementation of TPE and HP





PRISMALUNG*

The **PrismaLung** blood-gas exchanger allows for low-flow ECCO₂R:

- With the **Prismaflex** SW 8.1 system, you can run both ECCO₂R and CRRT treatments at the same time via one single vascular access, or perform each therapy independently
- Like CRRT, ECCO₂R therapy is easily managed with a specific **PrismaLung** software modality that guides the user through each step of the treatment set-up

FLEXITRATE

Fully integrated citrate and calcium management enables delivery of regional citrate anticoagulation for all CRRT modalities:

- Protocols for CVVH and CVVHDF with automated citrate and calcium delivery for effective and easy implementation
- All parameters, such as the citrate dose or flow rates, are displayed and easily accessible on the interactive user interface

The **Prismaflex** RCA concept combines two mechanisms to prolong extracorporeal circuit lifespan:

1. Pre-dilution of the blood^{11,12}
2. Use of a low-concentrated citrate solution in place of systemic heparin, which inhibits the coagulation cascade by chelating free ionised calcium^{13,14}

MARS*

The **MARS** system removes both protein-bound and water-soluble substances that accumulate in the plasma of patients with liver failure.^{15–17} A specific modality on the **Prismaflex** system greatly simplifies implementation of **MARS** therapy, making it more accessible to every hospital:

- A dedicated user interface displays on-line instructions to guide the user in the therapy set-up
- Unique **X-MARS** kit specifically designed for connection with the **MARS** components and contains all the necessary disposables
- **X-MARS** kit on the **Prismaflex** system is designed to provide liver support in combination with CRRT

*The **Prismaflex** system powers a wide range of extracorporeal blood purification therapies for multi-organ support on one device.*

*Not yet available in every region or country. Please contact your local Baxter representative for additional information.
ECCO₂R, extracorporeal CO₂ removal; TPE, therapeutic plasma exchange; HP, haemoperfusion.

How can Baxter support you?

TRAINING

- **Qualified training specialists** provide helpful clinician education and share best practices
- **Baxter Education portal** provides online training for the **Prismaflex** system and associated therapies
 - Used by over 17,000 users annually*
 - Translated into 16 languages
- **Subject matter experts** including medical affairs for peer-to-peer discussions and problem solving

Baxter is your dedicated ICU partner. We work to understand the complex requirements of the ICU and provide ongoing support where it's needed most.

TECHNICAL SUPPORT

- **Dedicated technical support provided** – knowledge and services built upon years of meeting the distinctive needs of the ICU

RESEARCH

- **Research and development** – independent laboratory and clinical research to advance Baxter ICU products and therapies

SHARESOURCE CONNECT SOFTWARE

- **Simplified Connectivity to Patient Data Management System** automates bedside data capture throughout therapy delivery and provides clinic-specific insights across all **Prismaflex** devices in the ICU
- **Acute Therapy Analysis and Reporting** helps to identify trends in treatment delivery and improve therapy administration by displaying clinical questions related to filter life, risk factors for clotting, and treatment efficiency

*Baxter is committed to providing a comprehensive range of products and therapies. Our focus on the **Prismaflex** system platform together with service and clinical expertise help ICUs deliver optimised patient outcomes and workflows.*

Multi-organ support powered by Prismaflex




Prismaflex is a versatile, trusted machine with a comprehensive product offering. Baxter offers training, support and expertise to help deliver optimised outcomes for ICU.

References

1. Baxter – oXiris. Instructions for use, 2017.
2. Thomas M, *et al.* *Contrib Nephrol* 2011;173:119–129.
3. Caravetta P, *et al.* Abstract presented at the 18th International Conference on Continuous Renal Replacement Therapies, San Diego, CA, United States, February 12–15, 2013: 53.
4. Turani F, *et al.* Abstract presented at the 33rd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 19–22, 2013: P63.
5. Candidi F, *et al.* Abstract presented at the 27th Annual Meeting of the European Association of Cardiothoracic Anaesthesiologists, Amsterdam, The Netherlands, May 23–25, 2012: 0-56.
6. Shum HP, *et al.* *Hong Kong Med J* 2013;19:49–47.
7. Baxter – Rev.3 – oXiris Clinical Evaluation Report. Data on file, 2017.
8. Imahase H, *et al.* Abstract presented at Sepsis 2012, Paris, France, November 7–9, 2012: P10.
9. Broman M, *et al.* *Acta Anaesthesiol Scand* 2011;55:39–45.
10. Godaly G, *et al.* *Clinical Kidney Journal* 2016;9(2):205–10.
11. Uchino S, *et al.* *Nephron Clin Pract* 2003;94:c94–c98.
12. Van der Voort PHJ, *et al.* *Blood Purif* 2005;23:175–180.
13. Stucker F, *et al.* *Critical Care* 2015;19:91.
14. Zhang Z and Hongying N. *Intensive Care Med* 2012;38:20–28.
15. Hassanein TI, *et al.* *Hepatology* 2007;46:1853–1862.
16. Saliba F, *et al.* *Ann Intern Med* 2013;159:522–531.
17. Olin P, *et al.* *Scand J Gastroenterol* 2015;50:1127–1134.

What is the future?



PDMS, patient data management system.